Sodium glucose cotransporter 2 (SGLT2) inhibitors improve islet function in patients with type 2 diabetes by reducing plasma ketone body levels

In type 2 diabetes, the body either doesn't produce enough insulin or the cells become resistant to its effects, leading to high blood sugar levels. Insulin is a hormone that helps glucose (sugar) enter cells for energy. When the body can't use insulin effectively, glucose builds up in the bloodstream, a condition called hyperglycemia.

A newer class of medications called sodium-glucose cotransporter 2 (SGLT2) inhibitors has become popular in treating type 2 diabetes. These medications help lower blood sugar by causing the body to remove excess sugar through urine. Interestingly, SGLT2 inhibitors also seem to influence other processes in the body, such as fat breakdown and the production of ketones—small molecules that are created when fat is used for energy.

This research aims to understand how changes in ketone levels caused by SGLT2 inhibitors may affect the function of insulin-producing cells in the pancreas, called islet cells. By exploring this connection, the study may help doctors predict which patients will benefit most from SGLT2 inhibitors. Additionally, the findings could lead to the development of new treatments that target fat metabolism and insulin regulation, ultimately improving care for people with diabetes.

This study conducts a secondary analysis of existing clinical trial data to investigate the effects of SGLT2 inhibitors (e.g., dapagliflozin) on pancreatic islet function in patients with type 2 diabetes (T2D). By analyzing pre- and post-treatment biomarkers (e.g., blood glucose, insulin levels), we aim to evaluate whether these medications improve islet function. All data are sourced from completed clinical trial databases; no new patient recruitment is involved.

A longitudinal cohort study design will be used, meaning the same group of participants will be tracked over time. This approach allows researchers to observe how ketone levels and islet cell function change in response to SGLT2 inhibitor treatment. By collecting data from multiple hospitals and clinics, the study includes a wide range of participants, making the results more applicable to the general population. The use of reliable medical tests ensures accurate measurements, helping researchers draw meaningful conclusions about the relationship between ketone levels and islet cell function.